Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Et åbent udvidelsesstudie af ORKA-001 hos deltagere med plaque psoriasis

21. oktober 2026 opdateret af: Oruka Therapeutics, Inc.

Et åbent udvidelsesstudie til evaluering af den langsigtede sikkerhed, tolerabilitet og effektivitet af ORKA-001 hos deltagere med moderat til svær plaque-psoriasis

An open-label extension (OLE) study to evaluate the long-term safety and efficacy of ORKA-001 in adult participants with moderate-to-severe plaque psoriasis, who previously participated in an Oruka Therapeutics sponsored study.

Studieoversigt

Status

Rekruttering

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

This open-label extension study evaluates the long-term safety and efficacy of ORKA-001 in adults with moderate-to-severe plaque psoriasis. The study includes an open-label treatment period of up to approximately 96 weeks and a post-treatment follow-up period of approximately 48 weeks following the last study visit.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

240

Fase

  • Fase 2

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

    • Alberta
      • Edmonton, Alberta, Canada, T5J 3S9
        • Rekruttering
        • Oruka Therapeutics Investigative Site
        • Kontakt:
      • Edmonton, Alberta, Canada, T6G 1C3
        • Rekruttering
        • Oruka Therapeutics Investigative Site
        • Kontakt:
    • British Columbia
      • Surrey, British Columbia, Canada, V3R 6A7
        • Rekruttering
        • Oruka Therapeutics Investigative Site
        • Kontakt:
      • Surrey, British Columbia, Canada, V3V 0C6
        • Rekruttering
        • Oruka Therapeutics Investigative Site
        • Kontakt:
    • New Brunswick
      • Fredericton, New Brunswick, Canada, E3B IG9
        • Rekruttering
        • Oruka Therapeutics Investigative Site
        • Kontakt:
    • Ontario
      • Ajax, Ontario, Canada, L1S7K8
        • Rekruttering
        • Oruka Therapeutics Investigative Site
        • Kontakt:
      • London, Ontario, Canada, N6H 5L5
        • Rekruttering
        • Oruka Therapeutics Investigative Site
        • Kontakt:
      • Markham, Ontario, Canada, L3P 1X3
        • Rekruttering
        • Oruka Therapeutics Investigative Site
        • Kontakt:
      • Peterborough, Ontario, Canada, K9J 5K2
        • Rekruttering
        • Oruka Therapeutics Investigative Site
        • Kontakt:
      • Toronto, Ontario, Canada, M4W 2N4
        • Rekruttering
        • Oruka Therapeutics Investigative Site
        • Kontakt:
      • Waterloo, Ontario, Canada, N2J 1C4
        • Rekruttering
        • Oruka Therapeutics Investigative Site
        • Kontakt:
    • Quebec
      • Montreal, Quebec, Canada, H2X2V1
        • Rekruttering
        • Oruka Therapeutics Investigative Site
        • Kontakt:
      • Québec, Quebec, Canada, G1V4X7
        • Rekruttering
        • Oruka Therapeutics Investigative Site
        • Kontakt:
    • Arizona
      • Phoenix, Arizona, Forenede Stater, 85032
        • Rekruttering
        • Oruka Therapeutics Investigative Site
        • Kontakt:
    • Arkansas
      • North Little Rock, Arkansas, Forenede Stater, 72117
        • Rekruttering
        • Oruka Therapeutics Investigative Site
        • Kontakt:
    • California
      • Fountain Valley, California, Forenede Stater, 92708
        • Rekruttering
        • Oruka Therapeutics Investigative Site
        • Kontakt:
      • Los Angeles, California, Forenede Stater, 90045
        • Rekruttering
        • Oruka Therapeutics Investigative Site
        • Kontakt:
      • Los Angeles, California, Forenede Stater, 90095
        • Rekruttering
        • Oruka Therapeutics Investigative Site
        • Kontakt:
      • San Diego, California, Forenede Stater, 92123
        • Rekruttering
        • Oruka Therapeutics Investigative Site
        • Kontakt:
      • Santa Ana, California, Forenede Stater, 92701
        • Rekruttering
        • Oruka Therapeutics Investigative Site
        • Kontakt:
      • Santa Monica, California, Forenede Stater, 90403
        • Rekruttering
        • Oruka Therapeutics Investigative Site
        • Kontakt:
    • Connecticut
      • Cromwell, Connecticut, Forenede Stater, 06416
        • Rekruttering
        • Oruka Therapeutics Investigative Site
        • Kontakt:
    • Florida
      • Miami, Florida, Forenede Stater, 33126
        • Rekruttering
        • Oruka Therapeutics Investigative Site
        • Kontakt:
    • Illinois
      • Rolling Meadows, Illinois, Forenede Stater, 60008
        • Rekruttering
        • Oruka Therapeutics Investigative Site
        • Kontakt:
    • Indiana
      • Plainfield, Indiana, Forenede Stater, 46168
        • Rekruttering
        • Oruka Therapeutics Investigative Site
        • Kontakt:
    • Kentucky
      • Bowling Green, Kentucky, Forenede Stater, 42104
    • Maryland
      • Rockville, Maryland, Forenede Stater, 20850
        • Rekruttering
        • Oruka Therapeutics Investigative Site
        • Kontakt:
    • Massachusetts
      • Boston, Massachusetts, Forenede Stater, 02111
        • Rekruttering
        • Oruka Therapeutics Investigative Site
        • Kontakt:
    • Michigan
      • Detroit, Michigan, Forenede Stater, 48202
        • Rekruttering
        • Oruka Therapeutics Investigative Site
        • Kontakt:
    • New York
      • New York, New York, Forenede Stater, 10023
        • Rekruttering
        • Oruka Therapeutics Investigative Site
        • Kontakt:
      • New York, New York, Forenede Stater, 10029
        • Rekruttering
        • Oruka Therapeutics Investigative Site
        • Kontakt:
    • Ohio
      • Cleveland, Ohio, Forenede Stater, 44106
        • Rekruttering
        • Oruka Therapeutics Investigative Site
        • Kontakt:
      • Mason, Ohio, Forenede Stater, 45040
        • Rekruttering
        • Oruka Therapeutics Investigative Site
        • Kontakt:
    • Oregon
      • Portland, Oregon, Forenede Stater, 97201
        • Rekruttering
        • Oruka Therapeutics Investigative Site
        • Kontakt:
      • Portland, Oregon, Forenede Stater, 97210
        • Rekruttering
        • Oruka Therapeutics Investigative Site
        • Kontakt:
    • Texas
      • Frisco, Texas, Forenede Stater, 75033
        • Rekruttering
        • Oruka Therapeutics Investigative Site
        • Kontakt:
      • Houston, Texas, Forenede Stater, 77004
        • Rekruttering
        • Oruka Therapeutics Investigative Site
        • Kontakt:
      • Webster, Texas, Forenede Stater, 77598
        • Rekruttering
        • Oruka Therapeutics Investigative Site
        • Kontakt:
    • Virginia
      • Norfolk, Virginia, Forenede Stater, 23502
        • Rekruttering
        • Oruka Therapeutics Investigative Site
        • Kontakt:

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  1. Signed informed consent by participants from previous trial choosing to transition into the OLE.
  2. Participants who have successfully completed the preceding trial.
  3. For women of childbearing potential, must have a negative urine pregnancy test at Baseline visit.
  4. For women of childbearing potential and fertile male participants with a partner of childbearing potential must be willing to continue to use highly effective contraception

Exclusion Criteria:

  1. Participants who experienced any adverse events with ORKA-001 in the preceding trial that led to permanent investigational medicinal product discontinuation or, in the opinion of the Investigator, would preclude continued treatment with ORKA-001
  2. Participants who have developed guttate, erythrodermic or pustular psoriasis or drug-induced psoriasis (as diagnosed by the Investigator), during the preceding trial.
  3. Evidence of current or previous clinically significant disease, medical condition other than psoriasis, or finding during the medical examination that, in the opinion of the Investigator would compromise the safety of the participant or the quality of the data.
  4. Any clinically significant laboratory abnormality based on the last available lab results received during the preceding trial, that, according to the Investigator's medical assessment, precludes them from continued treatment with ORKA-001.
  5. Participant is pregnant or breastfeeding.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Ikke-randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: ORKA-001 Once Yearly (High Dose)

Participants will receive ORKA-001 once a year per OLE protocol.

ORKA-001 administered by subcutaneous (SC) injection

Eksperimentel: ORKA-001 Once Yearly (Low Dose)

Participants will receive ORKA-001 once a year per OLE protocol.

ORKA-001 administered by subcutaneous (SC) injection

Eksperimentel: ORKA-001 Twice Yearly

Participants will receive ORKA-001 every 6 months per OLE protocol.

ORKA-001 administered by subcutaneous (SC) injection

Ingen indgriben: No Drug

Participants will receive no drug until protocol defined PASI response criterion is met.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Incidence of Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Events (TESAEs), and TEAEs of Special Interest (TEAESIs)
Tidsramme: Day 1 through Week 144

Incidence of treatment adverse events, treatment-emergent serious adverse events, treatment adverse events of special interest, and potential clinically significant changes from baseline in vital signs, clinical laboratory parameters and electrocardiograms.

Day 1 through Week 144

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Proportion of Participants Maintaining PASI100 in the Subset of Participants Meeting the Criterion at Baseline of OLE
Tidsramme: Day 1 through Week 96

The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease).

Day 1 through Week 96
Proportion of Participants Maintaining PASI90 in the Subset of Participants Meeting the Criterion at Baseline of OLE
Tidsramme: Day 1 through Week 96

The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease).

Day 1 through Week 96
Proportion of Participants Maintaining Investigator's Global Assessment (IGA) 0 in the Subset of Participants Meeting the Criterion at Baseline of OLE
Tidsramme: Day 1 through Week 96

The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4).

Day 1 through Week 96
Proportion of Participants Maintaining Investigator's Global Assessment (IGA) 0/1 in the Subset of Participants Meeting the Criterion at Baseline of OLE
Tidsramme: Time Frame: Day 1 through Week 96

The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4).

Time Frame: Day 1 through Week 96
Proportion of Participants with an Improvement of their OLE Baseline PASI Score in the Subset of Participants who did not Achieve PASI75 at OLE Baseline
Tidsramme: Day 1 through Week 96

Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease).

Day 1 through Week 96
Time-to-loss of PASI100 in the Subset of Participants who achieved PASI100 at Baseline of OLE
Tidsramme: Day 1 through Week 96

The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease).

Day 1 through Week 96
Time-to-loss of PASI90 in the Subset of Participants who achieved PASI90 at Baseline of the OLE
Tidsramme: Day 1 through Week 96

The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease).

Day 1 through Week 96
PASI Score Over Time
Tidsramme: Day 1 through Week 96

The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease).

Day 1 through Week 96
IGA Score Over Time
Tidsramme: Day 1 through Week 96

The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4).

Day 1 through Week 96

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

23. februar 2026

Primær færdiggørelse (Anslået)

1. maj 2030

Studieafslutning (Anslået)

1. juli 2030

Datoer for studieregistrering

Først indsendt

26. februar 2026

Først indsendt, der opfyldte QC-kriterier

26. februar 2026

Først opslået (Faktiske)

4. marts 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

23. oktober 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

21. oktober 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • ORKA-001-113

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

UBESLUTET

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .